IL1B and myocardial infarction: A fully human monoclonal antibody directed against IL-1β, canakinumab, was previously presented following investigation in a large phase 3 trial for the prevention of recurrent myocardial infarction.22 The anti-inflammatory therapy at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering, in patients with previous myocardial infarction.